Edwards Lifesciences Corporation (EW)
NYSE · Irvine, California, USA · Founded 1958 · CEO Bernard Zovighian
Valuation summary
$68.28 fair value versus $103.88 in the market, a difference of -34.3%. Rated Sell.
| Fair value per share | $68.28 |
| Current share price | $103.88 |
| Upside / downside | -34.3% |
| Bear case | $47.14 |
| Bull case | $98.38 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.80% |
| Market capitalisation | $60B |
| EV / Sales | 8.8x |
About Edwards Lifesciences Corporation
Traces to Miles Lowell Edwards, who built the first artificial heart valve in 1958, and separated from Baxter in 2000. Bernard Zovighian has been CEO since 2023. Edwards dominates transcatheter aortic valve replacement — replacing a heart valve via catheter rather than open-heart surgery, which makes the procedure available to patients too frail for surgery.
Investment case
- Clear leadership in transcatheter aortic valves with strong clinical evidence behind it.
- The eligible patient population keeps expanding as trials extend into lower-risk groups.
- Mitral and tricuspid programmes open genuinely large new markets.
Key risks
- Aortic valve growth has decelerated as the initial market matures.
- Medtronic and Abbott compete directly and are investing heavily.
- Hospital procedure capacity and staffing limit how fast volumes can grow.
Recent developments
- 2026-10-07 · Edwards will host its next earnings call on 4 November 2026, after a TCT investor event on 2 November. source
- 2026-10-01 · FDA approved the AUTUS valve, the first surgical pulmonary valve for paediatric patients. source
- 2026-09-10 · CMS issued an updated TAVR national coverage determination; Edwards said it expands patient access and reiterated 2026 guidance. source
Revenue by segment
| Transcatheter Aortic Valve | 62% |
| Surgical Structural Heart | 17% |
| Transcatheter Mitral & Tricuspid | 21% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $7.6B | $1.6B |
| Year 2 | $8.5B | $1.8B |
| Year 3 | $9.5B | $2.0B |
| Year 4 | $10.4B | $2.2B |
| Year 5 | $11.4B | $2.3B |
What the street says
The franchise quality is not disputed; the growth rate is. The updated Medicare coverage policy for transcatheter aortic valves issued in September 2026 is seen as widening patient access, though Edwards says adoption will take time. Mitral and tricuspid growth and the 2027 outlook due at the December investor conference are the swing factors.
Comparable companies: IDXX · A · RMD · REGN · VRTX · SNY · ABT · ISRG
Open the interactive model, price chart and sensitivity grid →